Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | Bunctional PD-1 x αCD3 x αCD33 CiTE for AML

Marion Subklewe • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies Checkpoint inhibitors

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the bunctional PD-1 x αCD3 x αCD33 checkpoint inhibitory T cell-engaging (CiTE) antibody for acute myeloid leukemia. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Marion Subklewe

Immunotherapy in AML: translational insights and promising avenues being explored 17:15
Immunotherapy in AML: translational insights and promising avenues being explored
Ann-Kathrin Eisfeld et al. • 20 Sep 2025
Immunotherapeutics in AML
Amer Zeidan et al. • 29 Sep 2022
T-cell engagers and CARs in myeloid malignancies 12:20
T-cell engagers and CARs in myeloid malignancies
Andrew Kuykendall et al. • 13 Apr 2025
Optimizing bridging therapy before CAR-T in patients with lymphoma 2:56
Optimizing bridging therapy before CAR-T in patients with lymphoma
Marion Subklewe • 1 Apr 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals